Entries by nacnkcell

ONK Therapeutics and Trinity College Dublin Collaborate in an Enterprise Ireland Funded Project to Optimize Metabolism of NK Cells for Improved Cancer Therapies

Collaboration between ONK Therapeutics and Dr. David Finlay’s group at Trinity College Dublin, Ireland Two-year Enterprise Ireland Innovation Partnership Programme (IPP) project grant of €373,295 Research to explore metabolic reprogramming and engineering of natural killer (NK) cells for improved cancer therapy Galway, Ireland and San Diego, USA, 8 June  2021 – ONK Therapeutics Ltd, an […]

ONK Therapeutics Enters into a Research Agreement with NUI Galway to Support Optimization of its Dual-Targeted NK Cell Therapy against AML

Agreement with the National University of Ireland, Galway (NUI Galway), supervised by leading expert in the cellular environment in Acute Myeloid Leukaemia (AML), Dr. Eva Szegezdi Funded by ONK Therapeutics, the research will support engineering and optimization of its dual-targeted NK cell therapy candidate for AML (ONKT104) Aims to explore the potential added benefit of certain gene […]

ONK Therapeutics Appoints Professor Philippe Moreau to its Scientific Advisory Board

Professor Philippe Moreau brings 20 years of experience in clinical hematology Translational research head at University Hospital of Nantes, France World-renowned expert in multiple myeloma, leading clinical trials Joins US-based SAB members, Prof Malcolm Brenner MD, Ph.D. and Prof Jeffrey Miller MD  Galway, Ireland, and San Diego, USA, 8 April 2021 – ONK Therapeutics Ltd, […]

ONK Therapeutics Strengthens its Cell Therapy Manufacturing Process with License for EBV-LCL Feeder Cell Line from NIH to Enhance NK Cell Expansion

License with NIH for intellectual property for a clinically-validated, GMP grade feeder cell line to enable robust natural killer (NK) cell expansion Enhances ONK Therapeutics’ evolving research efforts to scale up and support clinical trials Galway, Ireland, and San Diego, USA, 18 March  2021 – ONK Therapeutics Ltd, an innovative cell therapy company focused on […]